Bio-Rad Laboratories, Inc. (BIO) |
| 298.34 0.76 (0.26%) 07-14 16:00 |
| Open: | 294.42 |
| High: | 299.87 |
| Low: | 294.42 |
| Volume: | 227,777 |
| Market Cap: | 8,066(M) |
| PE Ratio: | 32.18 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Devices |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 356.24 |
| Resistance 1: | 305.00 |
| Pivot price: | 292.88 |
| Support 1: | 283.37 |
| Support 2: | 270.00 |
| 52w High: | 343.12 |
| 52w Low: | 236.73 |
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.
| EPS | 6.010 |
| Book Value | 255.370 |
| PEG Ratio | 4.01 |
| Gross Profit | 62.212 |
| Profit Margin (%) | 6.52 |
| Operating Margin (%) | 5.76 |
| Return on Assets (ttm) | 1.8 |
| Return on Equity (ttm) | 2.5 |
Mon, 13 Jul 2026
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Sun, 12 Jul 2026
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Sat, 11 Jul 2026
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - simplywall.st
Thu, 09 Jul 2026
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Wed, 08 Jul 2026
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Thu, 02 Jul 2026
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |